Suppliers and packagers for generic pharmaceutical drug: RISPERIDONE

RISPERIDONE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Shandong Luye	RYKINDO	risperidone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212849	NDA	Shandong Luye Pharmaceutical Co., Ltd.	72526-102-11	1 KIT in 1 KIT (72526-102-11) * 2 mL in 1 VIAL, SINGLE-DOSE (72526-202-01) * 2 mL in 1 SYRINGE, GLASS (72526-801-01)	2023-06-20
Shandong Luye	RYKINDO	risperidone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212849	NDA	Shandong Luye Pharmaceutical Co., Ltd.	72526-103-11	1 KIT in 1 KIT (72526-103-11) * 2 mL in 1 VIAL, SINGLE-DOSE (72526-203-01) * 2 mL in 1 SYRINGE, GLASS (72526-801-01)	2023-06-20
Shandong Luye	RYKINDO	risperidone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212849	NDA	Shandong Luye Pharmaceutical Co., Ltd.	72526-104-11	1 KIT in 1 KIT (72526-104-11) * 2 mL in 1 VIAL, SINGLE-DOSE (72526-204-01) * 2 mL in 1 SYRINGE, GLASS (72526-801-01)	2023-06-20

RISPERIDONE DRUG SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

Risperidone is an atypical antipsychotic medication used to treat schizophrenia, bipolar disorder, and irritability associated with autism. The drug's supply chain involves active pharmaceutical ingredient (API) manufacturers, finished dosage form (FDF) manufacturers, and distributors. Key geographical hubs for risperidone API production include China and India, with significant FDF manufacturing concentrated in Europe and North America. Patent expirations for the originator drug, Risperdal, have led to a robust generic market, increasing the number of potential suppliers and competition.

WHAT ARE THE PRIMARY ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURERS FOR RISPERIDONE?

The production of risperidone API is concentrated among a limited number of global manufacturers. These companies are critical nodes in the supply chain, responsible for synthesizing the core chemical compound.

• Key API Manufacturers:

  • Jubilant Life Sciences (India): A significant supplier of APIs, including risperidone, with established manufacturing capabilities.
  • Dr. Reddy's Laboratories (India): Another major Indian pharmaceutical company with a broad API portfolio, including risperidone.
  • Sun Pharmaceutical Industries (India): A leading global pharmaceutical company with extensive API manufacturing operations.
  • Teva Pharmaceutical Industries (Israel): While primarily known for FDFs, Teva also has API manufacturing capabilities.
  • Cipla (India): A prominent Indian pharmaceutical company engaged in API production.
  • Orchid Pharma (India): Has previously been a supplier of risperidone API.

• Geographic Concentration: The majority of risperidone API manufacturing is located in India, leveraging cost advantages and established chemical synthesis infrastructure. China also plays a role, though specific company names are less consistently publicized in open source for risperidone API.

• Regulatory Compliance: API manufacturers must adhere to Good Manufacturing Practices (GMP) and undergo inspections by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance with these standards is a prerequisite for supplying to regulated markets.

WHO ARE THE MAJOR FINISHED DOSAGE FORM (FDF) MANUFACTURERS FOR RISPERIDONE?

Following API production, risperidone is formulated into various dosage forms, primarily oral tablets, orally disintegrating tablets, and oral solutions. The FDF manufacturing sector is more fragmented due to the generic nature of the market post-patent expiry.

• Key FDF Manufacturers and Marketers:

  • Janssen Pharmaceuticals (a Johnson & Johnson company) (USA/Global): The originator of Risperdal, still markets the branded product in various regions.
  • Teva Pharmaceutical Industries (Israel): A leading generic manufacturer with risperidone tablets and other formulations available globally.
  • Mylan N.V. (now Viatris) (USA/Global): A significant player in the generic pharmaceutical market, offering risperidone products.
  • Sun Pharmaceutical Industries (India): Markets generic risperidone formulations in multiple countries.
  • Dr. Reddy's Laboratories (India): Offers generic risperidone products.
  • Accord Healthcare (UK/Global): A substantial supplier of generic pharmaceuticals in Europe and other markets, including risperidone.
  • Perrigo Company (USA/Global): Focuses on generic and private-label pharmaceuticals, including risperidone.
  • Apna Drugs (India): Manufactures and exports generic pharmaceuticals.

• Dosage Form Variations: Manufacturers offer risperidone in:

  • Oral tablets (e.g., 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg)
  • Orally disintegrating tablets (ODTs)
  • Oral solutions
  • Long-acting injectable formulations (e.g., Risperdal Consta), which are typically produced by innovator companies or specialized contract manufacturers.

• Contract Manufacturing Organizations (CMOs): Many FDF manufacturers, particularly smaller generic companies, utilize CMOs for production. These CMOs operate under strict quality agreements and regulatory oversight. Specific CMOs are often proprietary information tied to client contracts.

WHAT IS THE PATENT LANDSCAPE FOR RISPERIDONE?

The patent landscape for risperidone is characterized by the expiration of key composition of matter and formulation patents, paving the way for generic competition.

• Originator Patents: The primary patents for risperidone were held by Janssen Pharmaceutica. The key patent covering the composition of matter for risperidone expired in many major markets in the early to mid-2000s. For instance, the U.S. patent expired around 2003-2004, with extensions [1].

• Formulation and Method of Use Patents: While the core compound patent expired, secondary patents related to specific formulations (e.g., orally disintegrating tablets, long-acting injectables) and methods of use have also expired or faced challenges.

  • The patent for Risperdal Consta (long-acting injectable formulation), U.S. Patent No. 5,955,450, expired, allowing for generic competition. Generic versions of long-acting risperidone injectables have since been approved and marketed by companies like Mylan (now Viatris) and Teva.

• Generic Entry: The expiration of these patents allowed numerous generic manufacturers to enter the market, leading to significant price erosion and increased accessibility. Regulatory filings for generic risperidone are common at the FDA and EMA.

• Patent Litigation: In the past, there were instances of patent litigation as the originator sought to defend its market position, but these challenges did not fundamentally alter the generic availability post-primary patent expiry.

HOW ARE RISPERIDONE SUPPLY CHAINS REGULATED?

The supply chain for risperidone is subject to stringent regulatory oversight by health authorities worldwide to ensure product safety, efficacy, and quality.

• Good Manufacturing Practices (GMP): All facilities involved in the manufacturing of risperidone API and FDFs must comply with GMP standards. These regulations cover all aspects of production, from raw material sourcing to finished product testing and distribution. Regulatory bodies conduct regular inspections of manufacturing sites.

  • FDA GMP Regulations: 21 CFR Parts 210 and 211.
  • EMA GMP Guidelines: EudraLex Volume 4.

• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies like the FDA. These confidential documents provide detailed information about the manufacturing process, quality controls, and facilities for the API. FDF manufacturers reference these DMFs in their drug applications.

• Abbreviated New Drug Applications (ANDAs): Generic FDF manufacturers submit ANDAs to the FDA, demonstrating that their product is bioequivalent to the reference listed drug (RLD) and manufactured under GMP conditions.

• Marketing Authorization Applications (MAAs): In Europe, generic risperidone products require an MAA submitted to the EMA or national competent authorities.

• Quality Control and Testing: Rigorous quality control testing is mandated at each stage of production, including raw material analysis, in-process testing, and finished product release testing for identity, purity, strength, and dissolution.

• Traceability and Serialization: Regulations such as the U.S. Drug Supply Chain Security Act (DSCSA) and the EU Falsified Medicines Directive (FMD) require product serialization and traceability to prevent counterfeit drugs from entering the legitimate supply chain.

WHAT ARE THE KEY GEOGRAPHIC MARKETS AND DISTRIBUTION CHANNELS FOR RISPERIDONE?

Risperidone is a globally distributed medication, with key markets in developed countries and increasing access in emerging economies. Distribution channels are typical for pharmaceutical products.

• Major Geographic Markets:

  • North America (USA, Canada): Large markets with significant demand for both branded and generic risperidone.
  • Europe (Germany, UK, France, Spain, Italy): Mature markets with a substantial generic presence.
  • Asia-Pacific (India, China, Japan, Australia): Growing markets with increasing healthcare access. India and China are also significant API production hubs.
  • Latin America: Emerging markets with expanding access to antipsychotic medications.

• Distribution Channels:

  • Wholesalers and Distributors: The primary channel for moving FDFs from manufacturers to pharmacies and hospitals. Major global distributors include AmerisourceBergen, Cardinal Health, and McKesson. National distributors also play a role.
  • Pharmacies (Retail and Hospital): Dispense finished prescription medications to patients.
  • Hospitals and Clinics: Directly procure and administer risperidone, particularly for inpatient care and long-acting injectable formulations.
  • Government Tenders and Public Health Programs: In many countries, government entities procure large volumes of essential medicines like risperidone for public health initiatives and formularies.

• Market Dynamics: The generic nature of risperidone has led to intense competition, with price being a significant factor. Supply chain efficiency and reliable sourcing of API are critical for generic manufacturers to maintain competitiveness.

HOW DOES THE SUPPLY OF RISPERIDONE API COMPARE BETWEEN DIFFERENT MANUFACTURERS?

The comparison of risperidone API supply among manufacturers focuses on capacity, quality, regulatory compliance, and cost.

• Capacity and Scale: Manufacturers like Jubilant Life Sciences, Dr. Reddy's, and Sun Pharma possess significant manufacturing capacities to meet global demand. Their ability to produce large volumes efficiently is a key competitive advantage.

  • Jubilant Life Sciences: Known for its broad portfolio and large-scale API production capabilities across various therapeutic areas.
  • Dr. Reddy's Laboratories: Has robust API manufacturing infrastructure, supporting its own FDF production and external sales.
  • Sun Pharmaceutical Industries: Operates extensive manufacturing sites, enabling high-volume API production.

• Quality and Regulatory Track Record: Manufacturers with a strong history of successful FDA and EMA inspections and a robust quality management system are preferred. A history of warning letters or import alerts can disqualify a supplier. Companies with successful DMF filings and approvals are considered reliable.

• Cost Competitiveness: API pricing is a critical factor, especially for generic FDF manufacturers. Manufacturers in India and China generally offer more competitive pricing due to lower labor and operational costs. However, quality and reliability must be balanced against cost.

• Supply Chain Resilience: Manufacturers with diversified production sites and robust business continuity plans are more resilient to disruptions (e.g., geopolitical events, natural disasters, regulatory issues). Companies that manage their own upstream raw materials can further enhance resilience.

• Lead Times and Reliability: Consistent lead times and on-time delivery are crucial for FDF manufacturers to manage inventory and avoid stockouts. Reliable communication and proactive issue resolution are hallmarks of preferred API suppliers.

WHAT ARE THE POTENTIAL RISKS AND MITIGATION STRATEGIES IN THE RISPERIDONE SUPPLY CHAIN?

The risperidone supply chain faces several risks common to pharmaceutical manufacturing and distribution.

• API Source Concentration: Heavy reliance on a few API manufacturers, particularly in specific geographic regions, creates vulnerability.

  • Mitigation: Dual or multi-sourcing of API from different qualified suppliers, preferably in different geographic locations. Building strategic partnerships with key suppliers.

• Regulatory Changes and Compliance Issues: Stricter GMP enforcement, new environmental regulations, or a supplier's failure to maintain compliance can disrupt supply.

  • Mitigation: Continuous monitoring of regulatory landscapes. Conducting thorough due diligence and regular audits of suppliers. Maintaining robust internal quality systems.

• Geopolitical Instability and Trade Barriers: Trade disputes, tariffs, or political unrest in key manufacturing countries can impact the availability and cost of APIs and FDFs.

  • Mitigation: Diversifying manufacturing and sourcing locations. Understanding trade agreements and tariff implications. Maintaining buffer stock where feasible.

• Quality Defects and Recalls: Manufacturing errors leading to product recalls can cause significant supply disruptions and reputational damage.

  • Mitigation: Implementing stringent quality control measures throughout the supply chain. Robust change control procedures. Detailed batch traceability.

• Logistics and Transportation Disruptions: Shipping delays, port congestion, or natural disasters affecting transportation routes can impact delivery schedules.

  • Mitigation: Working with multiple logistics providers. Utilizing diverse transportation modes. Establishing regional distribution centers.

• Counterfeiting and Diversion: The generic nature of risperidone can make it a target for counterfeiters and diversion from legitimate supply chains.

  • Mitigation: Implementing serialization and track-and-trace systems (DSCSA, FMD). Robust authentication measures at each supply chain touchpoint. Close collaboration with regulatory authorities.

KEY TAKEAWAYS

• Risperidone API production is primarily concentrated in India, with key suppliers including Jubilant Life Sciences, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries.
• The FDF manufacturing market is competitive and includes global generics giants like Teva, Viatris (Mylan), and Sun Pharma, alongside originator Janssen.
• The patent expiry of risperidone's composition of matter and key formulations has facilitated a robust generic market.
• The entire supply chain, from API synthesis to FDF distribution, is subject to strict GMP regulations enforced by agencies like the FDA and EMA.
• North America and Europe represent the largest geographic markets, while distribution relies heavily on wholesalers, pharmacies, and healthcare institutions.
• Risks in the supply chain include API source concentration, regulatory compliance, geopolitical instability, quality issues, and logistical disruptions, all of which require proactive mitigation strategies such as dual-sourcing and robust quality management.

FREQUENTLY ASKED QUESTIONS

1. Which countries are the primary exporters of risperidone API? India is the dominant exporter of risperidone API, with China also being a significant, albeit less transparent, supplier.

2. What is the typical lead time for API orders of risperidone from Indian manufacturers? Lead times can vary but typically range from 4 to 12 weeks from order placement to delivery, depending on supplier stock levels, production schedules, and shipping logistics.

3. Are there any critical quality attributes that distinguish risperidone API from different suppliers? Critical quality attributes include purity (e.g., absence of specified impurities like 9-hydroxyrisperidone), polymorphic form, particle size distribution, and compliance with pharmacopeial monographs (e.g., USP, EP). Variations can affect FDF formulation performance and stability.

4. How does the demand for risperidone orally disintegrating tablets (ODTs) influence API supplier selection? ODTs require specific API characteristics, such as controlled particle size and flow properties, to ensure consistent dissolution and disintegration. API suppliers with expertise in producing materials suitable for these specialized formulations may be preferred.

5. What is the average price range for risperidone API per kilogram in the current market? The average price for risperidone API can fluctuate based on volume, supplier, and market conditions but generally ranges from $150 to $400 per kilogram. This is a highly competitive segment, and prices are subject to frequent adjustment.

CITATIONS

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book Website]. (Specific patent expiry dates are publicly available via FDA databases and patent search engines.)